Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;159(1):350-357.
doi: 10.1053/j.gastro.2020.04.012. Epub 2020 Apr 10.

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

David T Rubin  1 , Joseph D Feuerstein  2 , Andrew Y Wang  3 , Russell D Cohen  4
Affiliations

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

David T Rubin et al. Gastroenterology. 2020 Jul.

Abstract

The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology.

Keywords: Coronavirus; Crohn’s Disease; IBD; Immunosuppression; SARS-CoV-2; Ulcerative Colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Management of patients with IBD during the COVID-19 pandemic. 5-ASA, 5-aminosalicylic acid medication; CRP, C-reactive protein; mAb, monoclonal antibodies. ∗Symptoms and findings of COVID-19: fever (83%–99%); cough (59%–82%); fatigue (44%–70%); anorexia (40%–84%); shortness of breath (31%–40%); sputum production (28%–33%); myalgias (11%–35%); headache, confusion, rhinorrhea, sore throat, hemoptysis, vomiting, and diarrhea (<10%); lymphopenia (83%); computed tomography chest: bilateral, peripheral, ground-glass opacities. ∗∗Clearance of SARS-Cov-2 may enable resumption of IBD therapy; role of serologic antibody testing unclear at the current time. (Viral clearance testing may or may not be possible or appropriate, given local testing capabilities and health system-approved epidemiological testing strategies during the COIVD-19 pandemic.) ∗∗∗Treatment of COVID-19 under investigation, consider therapies that have safety and efficacy in IBD.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sultan S, Lim JK, Altayar O, et al. AGA Institute rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic [published online ahead of print March 31, 2020]. Gastroenterology 10.1053/j.gastro.2020.03.072. - DOI - PMC - PubMed
    1. Coronavirus. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Available at:
    1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [published online ahead of print March 13, 2020]. JAMA Intern Med 10.1001/jamainternmed.2020.0994. - DOI - PMC - PubMed
    1. Xu Y. Unveiling the origin and transmission of 2019-nCoV. Trends Microbiol. 2020;28:239–240. - PMC - PubMed
    1. van Doremalen N., Bushmaker T., Morris D.H. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–1567. - PMC - PubMed

MeSH terms

Substances